A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative

ID Number 13-0712

Principal Investigator(s)
Anthony Manasia

Department(s) or Division(s)


The purpose of this study is to test an investigational antibiotic called Amikacin plus standard of care treatment for pneumonia and compare it to standard of care treatment alone. Amikacin has already been approved by the Food and Drug Administration for use in patients with certain types of infection when given orally or by injection. In this study, amikacin will be given a new way (inhaled) that has not been approved. Patients may qualify for this study if they have pneumonia, and require a breathing tube and mechanical ventilation machine to help them breath.  Pneumonia is a condition in which your lungs become infected by bacteria, viruses or other disease-causing organisms. These types of infections will cause inflammation (swelling and fluid in the lungs).

Contact Information
Bridget Twohig
(212) 241-3149

Recruiting Patients: Yes